Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
HLA|July 3, 2018
Identification of seven novel HLA class I and II allelesSylvie Ferrari-Lacraz, Dominique Masson, Jean Villard, et al.Swiss Medical Weekly|September 1, 2012
HLA and non-HLA polymorphisms in renal transplantationStéphanie Laperrousaz, Stéphanie Tiercy, Jean Villard, et al.HLA|May 6, 2020
Characterization of the novel HLA-DQB1*03:01:46 variant allele in a French hematopoietic stem cell donorCéline Dard, Ornella Senoussi, Sylvie Ferrari-Lacraz, et al.Transplant Immunology|August 27, 2014
Expression of killer cell immunoglobulin-like receptors (KIRs) by natural killer cells during acute CMV infection after kidney transplantationCasimir de Rham, Karine Hadaya, Cédric Bandelier, et al.European Journal of Gastroenterology & Hepatology|June 15, 2006
Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumourAlexandre Pariente, Francine Etcharry, Valérie Cales, et al.Swiss Medical Weekly|March 6, 2015
Kidney paired donation: a plea for a Swiss National ProgrammeKarine Hadaya, Thomas Fehr, Barbara Rüsi, et al.International Immunology|June 17, 2008
IL-21 promotes survival and maintains a naive phenotype in human CD4+ T lymphocytesSylvie Ferrari-Lacraz, Rachel Chicheportiche, Gregory Schneiter, et al.European Cytokine Network|May 23, 2012
Contact with stimulated T cells up-regulates expression of peptidylarginine deiminase 2 and 4 by human monocytesSylvie Ferrari-Lacraz, Mireille Sebbag, Rachel Chicheportiche, et al.Multiple Sclerosis International|March 25, 2021
No Early Effect of Intrathecal Rituximab in Progressive Multiple Sclerosis (EFFRITE Clinical Trial)Mickael Bonnan, Sylvie Ferrari, Henri Courtade, et al.Current Drug Targets|October 31, 2014
Intrathecal rituximab therapy in multiple sclerosis: review of evidence supporting the need for future trialsMickael Bonnan, Sylvie Ferrari, Eric Bertandeau, et al.Pageof 6